Sign In
Last checked at 
30 Nov 2021 07:00
Block Listing Six Monthly Return
30 November 2021
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).
Date: 1 June 2021
Name of applicant: | Futura Medical Plc | |||
Name of scheme: | Unapproved Share Option Scheme Unapproved Share Incentive Scheme EMI Share Option Scheme | |||
Period of return: | From: | 1 June 2021 | To: | 30 November 2021 |
Balance of unallotted securities under scheme(s) from previous return: | 7,811,779 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | n/a | |||
Less: Number of securities issued/allotted under scheme(s) during period: | (80,000) | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 7,731,779 | |||
Number and class of securities originally admitted and the date of admission | USOS Total: 3,882,912 814,424 25 May 2011 1,202,280 8 October 2013 1,466,208 25 May 2017 400,000 30 May 2018
USIS Total: 425,000 425,000 30 November 2018
EMI Total: 7,012,088 1,520,576 25 May 2011 1,467,720 8 October 2013 1,893,792 25 May 2017 790,000 30 May 2018 1,340,000 30 November 2018 | |||
For further information please contact:
Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:LiberumRichard Lindley/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel +44 (0) 20 3922 0891
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED. MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
Follow the stocks
